CTLA4 and neoplasm: Further, the HDAC inhibitor, entinostat, in combination with the checkpoint inhibitors anti–PD-1 and anti–CTLA-4, led to a significant suppression of G-MDSCs in the TME and significantly improved tumor-free survival in HER2/neu transgenic BC mouse model (74).